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Abstract
Purpose of Review This review seeks to investigate three
questions: What is the prevalence of comorbid psychiatric
diagnoses among pregnant women with opioid use disorder
(OUD)? How do comorbid psychiatric illnesses impact preg-
nant women with OUD? And how do comorbid psychiatric
illnesses affect the ability of pregnant women with OUD to
adhere to and complete OUD treatment?
Recent Findings Based on this literature review, 25–33% of
pregnant women with OUD have a psychiatric comorbidity,
with depression and anxiety being especially common.
However, of the 17 studies reviewed only 5 have prevalence
rates of dual diagnosis in pregnant women with OUD as their
primary outcome measures, their N’s were typically small,
methods for determining psychiatric diagnosis were variable,
and many of the studies were undertaken with women pre-
senting for treatment which carries with its implicit selection
bias. Of the women enrolled in treatment programs for SUD,
those with psychiatric comorbidity were more likely to have
impaired psychological and family/social functioning than
those without psychiatric comorbidity. Greater severity of co-
morbid psychiatric illness appears to predict poorer adherence
to treatment, but more research is needed to clarify this rela-
tionship with the psychiatric illness is less severe.
Summary While cooccurrence of psychiatric disorders in
pregnant women with opioid use disorder appears to be com-
mon, large population-based studies with validated diagnostic
tools and longitudinal assessments are needed to obtain defin-
itive rates and characteristics of cooccurring illnesses.
Integrated prenatal, addiction, and psychiatric treatment in a
setting that provides social support to pregnant patients with
OUD is most effective in maintaining women in treatment.
More research is still needed to identify optimal treatment
settings, therapy modalities, and medication management for
dually diagnosed pregnant women with OUD.
Keywords Pregnant . Dual diagnosis . Comorbidity .
Substance use disorder . Addiction . Opioid . Psychiatric
disorder
Introduction
Misuse of opioids, both prescription pain medication and her-
oin, is a public health crisis in the USA that is linked to
skyrocketing morbidity and mortality rates, health care costs,
criminal justice expenditures, and productivity loss. The rate
of increase in opioid misuse has been particularly acute in
women of reproductive age, producing a surge in opioid use
disorder (OUD) among pregnant women [1]. A study of over
57 million births in the USA between 1998 and 2011 found a
127% increase in the rate of women diagnosed with opioid
abuse or dependence at the time of delivery [2]. As compared
to men with OUD, women with OUD are more likely to be
younger, victims of emotional, physical, or sexual abuse,
experiencing other mental health concerns (including depres-
sion and anxiety), and prescribed psychiatric medications [3].
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Medical providers and other treatment experts regard preg-
nancy as an especially important time for medical intervention
in substance use disorder (SUD), often motivating women to
make lifestyle changes and reduce substance use. For exam-
ple, the prevalence of cigarette smoking declines from 23%
among women before pregnancy to 15% during pregnancy,
alcohol use declines from 55 to 10%, and illicit substance use
declines from 10 to 5% [4]. Women who continue to use
substances during their pregnancies face several barriers to
achieving sobriety. External barriers to treatment include in-
adequate finances, lower educational achievement, lack of
childcare, limited engagement with the labor market, and long
wait for appointments [5]. Studies have found that pregnant
women have relatively high dropout rates even in studies of
programs providing intensive psychosocial support [6]. This
suggests that there may be other barriers that pregnant women
with OUD are facing, and studies have found internal barriers
of shame, fear of judgment by health care providers, fear of
referral to social services, and losing custody of children [5].
Rates of mood and anxiety disorder have been found to
increase during pregnancy and thus may also be higher in
pregnant women with OUD compared to nonpregnant
women with OUD, and this may be an additional factor
influencing pregnant women’s ability to engage in treat-
ment [7]. Patients with non-SUD psychiatric illness have
impairments in neurobiological pathways like those in pa-
tients with SUD, which predispose patients with non-
SUD’s to developing a SUD and in some ways, complicates
these patients’ illness course [8–10].
Researchers currently have only a limited understanding of
the prevalence and variety of psychiatric comorbidity in preg-
nant women with OUD and the effect of dual diagnosis on
illness severity and treatment outcomes. Even comprehensive
caremodels for pregnant womenwith OUD, such as programs
with antenatal care, may not incorporate psychiatric assess-
ment as part of their intake process [11, 12]. Extensive re-
search has gone into investigating the safety for mother and
fetus of usingMedicationAssisted Treatment (MAT), but little
guidance can be found on what psychiatric medication to use
to treat the cooccurring illnesses that these women face while
pregnant [13].
To broaden this knowledge, the authors performed a liter-
ature review of current published studies that address OUD in
pregnant women and selected studies of comorbidity preva-
lence rates and treatment impact for closer evaluation. Three
research questions were asked. First, how prevalent are co-
morbid psychiatric diagnoses among pregnant women with
OUD? Second, how do comorbid psychiatric illnesses impact
the illness severity in pregnant women with OUD? Finally,
how do comorbid psychiatric illnesses impact treatment ad-
herence in pregnant women with OUD? The answers to these
research questions could be used to improve treatment pro-
grams and thus clinical outcomes, function, and health among
an understudied, vulnerable population. Based on these re-
sults, the authors proffer recommendations for treatment pro-
grams and suggestions for future research.
Methods
In August 2016, the authors searched Ovid MEDLINE(R),
Ovid MEDLINE(R) Daily Update, and Ovid MEDLINE (R)
In-Process & Other Non–Indexed Citations for subject
(MeSH) headings for pregnancy, opioid treatment, opioid-
related disorders, demography, and geographical location.
The search returned a total of 914 articles (see Appendix for
complete strategy), starting in 1946. Non-English language
publications, comments, and animal studies were excluded,
resulting in 719 articles. Importantly, of these 719 articles,
230 focused on neonatal abstinence syndrome, birth out-
comes, or childhood outcomes rather than on the mother’s
health. Articles that did not discuss maternal health were man-
ually excluded leaving a total of 489 articles. From this group
of 489 articles, the following were manually excluded:
nonoriginal research studies (e.g., guidance documents with-
out original results), studies that were literature reviews and
case reports/series with sample sizes of less than 30, and stud-
ies that did not examine the intersection of OUD and comor-
bid psychiatric disorders in pregnant women, leaving a total of
31 articles. Three further studies were included, which had
subjects with OUD but reported aggregate results for all pa-
tients with SUD (including patients with and without opioid
use disorder). Included, for example, is a study by Haller et al.
in which only 9% of subjects with SUD had OUD, because
few other studies discussed personality disorders and psychot-
ic illnesses among pregnant women with SUD [14]. Results
from Moylan et al.’s study, in which 56% of subjects were
enrolled in methadone maintenance programs, and results
from Eggleston et al.’s study, in which 89% of subjects had
OUD diagnosis, were also included in the review [15, 16••].
Results
Prevalence
The authors found 21 studies discussing the prevalence of
comorbid psychiatric disorders in pregnant women with
OUD. They excluded four of these studies for the following
reasons. One study (Gordon et al. 2012) avoided patients with
mental health conditions whose medications might interact
with maintenance therapy or affect pregnancy outcomes, po-
tentially biasing prevalence rates, two studies (Lacroix et al.
2011; Lund et al. 2013) examined prevalence of prescriptions
for comorbid psychiatric conditions rather than diagnoses, and
one study (Perry et al. 2015) had a small sample size (n = 15)
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[17–20]. After excluding these studies, our final analysis
contained 17 studies discussing the prevalence of comorbid
psychiatric disorders in pregnant women with OUD.
Methodology, sampling strategy, and study design varied
greatly among these studies, making comparisons difficult.
Settings also varied, both in terms of geography (England,
Australia, and the USA) and medical practice environment
(hospitals, outpatient clinics, or both). Prevalence of comorbid
psychiatric conditions in pregnant women with OUD was a
primary study outcome in only five studies (Ordean et al.
2013; Steer and Schut 1980; Holbrook and Kaltenbach
2012; Burns et al. 1985; Benningfield et al. 2010). The com-
bined total sample size for these five studies was 531 partici-
pants. Prevalence rates from other studies may be subject to
sampling bias due different primary study outcomes. Of the
five studies that included comorbid psychiatric conditions as a
primary outcome, three reported validated screening measures
(Steer and Schut 1980; Burns et al. 1985; Benningfield et al.
2010), but only one study (Benningfield et al. 2010) occurred
in the last 10 years.
Psychiatric diagnoses were not always obtained using val-
idated screening tools. Only 10 of the 17 studies discussing
prevalence clearly used a validated screening tool during pa-
tient interviews (see Table 1). Prevalence rates from 2 of these
10 studies (Benningfield et al. 2010 and Benningfield et al.
2012) should be interpreted with caution: They conducted
secondary analysis of a larger study (the Maternal Opioid
Treatment: Human Experimental Research (MOTHER
study). The MOTHER study had used the Mini International
Neuropsychiatric Interview (MINI) to putatively diagnose
psychiatric disorders. Additionally, more patients were report-
ed to use mental health medication during the MOTHER
study than were diagnosed with mental health conditions at
treatment entry, suggesting that prevalence rates are underes-
timates [17, 18]. Of the remaining studies, three examined
only medical records data (Ordean et al. 2013; Patel et al.
2013), two studies used aggregated institutional data reported
to the US government (Martin et al. 2015; Terplan et al. 2010;
Oei et al. 2009), one study conducted patient interviews with-
out the use of a validated screening tool (Greig et al. 2012),
and one study did not clarify how psychiatric diagnoses were
obtained (Tuten et al. 2012) [23–25, 26••, 27–29]. Prevalence
rates based solely on medical records or institutional reports
should be interpreted with caution, since it is impossible to
ascertain whether the healthcare provider used a validated
screening tool.
Other factors also bespeak caution. Many studies assessed
psychiatric conditions before OUD treatment began (see
Table 1); however, previous research has demonstrated that
certain psychiatric symptoms may diminish after OUD treat-
ment commences. In contrast, some studies obtained preva-
lence rates after OUD treatment had begun. Ideally, studies
should assess prevalence longitudinally. One study examined
prevalence longitudinally (Greig et al. 2012), but usedmedical
records to assess prevalence in time 1 and used a validated
screening tool in time 2, limiting the longitudinal results’ re-
liability [19].
Studies reported high rates of comorbid psychiatric disor-
ders in pregnant women with OUD, with rates ranging from
72 to 21%. Fitzimons et al. found a 72% prevalence rate,
Benningfield et al. and Eggleston each found prevalence rates
of over 60%, Oei et al. and Patel et al. each found a 45%
prevalence rate, Martin et al. found a 31% prevalence rate,
Greig et al. found a 25% prevalence rate, and Terplan et al.
found a 21% prevalence rate [16••, 22••, 23–25, 26••, 27, 28].
Moylan et al. found a prevalence rate of 32% for Axis I dis-
orders and 23% for Axis II disorders. Furthermore, the rate of
pregnant women with OUD with at least one comorbid psy-
chiatric disorder more than doubled since 1992 [15, 20].
Only a few studies compared prevalence rates between
groups. Using a cross-sectional study, Steer and Schut com-
pared the rate of mood disorders between pregnant women
with OUD and nonpregnant women with OUD, but did not
find a significant difference in prevalence rates between the
two groups. One study (Oei et al. 2009) found that pregnant
women with OUD and poly-substance use were more likely to
have comorbid psychiatric disorders than pregnant women
with OUD but without poly-substance use, and rates of nico-
tine use were not statistically significantly different between
the two groups (83.6 vs. 81.3%, p = 0.42) [21]. Chisolm et al.
and Eggleston et al. found that pregnant women with SUD
who smoked cigarettes were more likely to have comorbid
psychiatric disorders than nonsmoking pregnant women with
SUD (although almost 90% of the study sample smoked cig-
arettes) [22••]. Finally, in a cross-sectional study using medi-
cal records, Patel et al. found no statistically significant differ-
ence in rates of comorbid psychiatric conditions between
pregnant women with OUD undergoing buprenorphine treat-
ment, pregnant women with OUD not undergoing
buprenorphine treatment, and pregnant women with a
nonopioid substance use disorder [23].
Mood disorders are the most commonly reported comorbid
psychiatric disorders in pregnant women with OUD. Tuten
et al. reported a comorbid mood disorder rate of 58%, Tuten
reported a 56% comorbid mood disorder rate in methadone-
stabilized patients at treatment entry, and Fitzimons et al. re-
ported a 27% comorbid mood disorder rate in methadone-
stabilized patients at treatment entry [24, 25, 26••]. In the
studies reviewed, depression was the most commonly report-
ed mood disorder. Burns et al., Ordean et al., and Tuten et al.
each found a comorbid depression prevalence rate of around
50%, and Eggleston et al. found a rate of 38% [16••, 24, 27].
Interestingly, Burns et al. found that older pregnant women
with SUD exhibited significantly higher rates of depression
than did younger pregnant women with SUD. Greig et al.
found that antenatal depression predicted postnatal
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depression, although the study’s methodology may have
underestimated the depression rate at treatment entry [19].
Anxiety disorders were the second most commonly report-
ed comorbid psychiatric disorders in pregnant women with
OUD. Tuten et al. found an anxiety prevalence rate of 42%
in this population, Benningfield et al. found a prevalence rate
of 40%, and Fitzimmons et al. found a prevalence rate of 36%
[18, 24, 26••]. Multiple studies reported prevalence rates of
posttraumatic stress disorder (PTSD) in pregnant women with
OUD, Eggleston et al. found a 26% PTSD prevalence rate,
Moylan et al. found a 19% prevalence rate, Benningfield et al.
found a 16% prevalence rate, and Chisolm et al. found a 3%
prevalence rate. Minimal discussion of comorbid psychosis,
bipolar disorder, obsessive compulsive disorders, or eating
disorders existed in the literature [15, 16••, 22••]. Eggleston
et al. reported a 6% prevalence of bipolar disorder and a 2%
prevalence rate of eating disorder among pregnant women
with OUD at treatment entry. Notably, multiple studies ex-
cluded participants with symptoms of psychosis [16••].
Pregnant women with OUD frequently have more than one
comorbid psychiatric disorder. Tuten et al. reporting that 44%
of pregnant women with OUD had a mood disorder and an
anxiety disorder [25]. PTSD also frequently occurred with
other psychiatric disorders. In a cross-sectional study,
Moylan et al. found that pregnant women with both OUD
and PTSDwere twice as likely to have an additional comorbid
Axis I lifetime mood disorder (50 vs. 27%, P < .05) and twice
as likely to have an additional comorbid Axis II lifetime per-
sonality disorder as compared to pregnant women with OUD
but without PTSD [15]. In a cross-sectional study, Eggleston
et al. found that pregnant women with OUD and PTSD ex-
hibited higher rates of current panic disorder and social anxi-
ety disorder than did pregnant women with OUD but without
PTSD [16••].
Impact of Dual Diagnosis on Pregnant Women Diagnosed
with Opioid Use Disorder
Of over 700 articles identified by our literature search, only
seven (Table 2) met our search criteria as research studies
exploring the impact of dual diagnosis on pregnant women
with OUD [14–18, 22••, 26••]. The seven articles primarily
discussed the impact of the following psychiatric diagnoses on
pregnant women with OUD: mood disorders (mostly depres-
sive illnesses), anxiety disorders, and PTSD. To establish di-
agnoses, four of the studies conducted Structured Clinical
Interview for DSM-IV (SCID) interviews, which is the gold
standard for determining formal psychiatric diagnosis in re-
search studies [15, 16••, 22••, 26••]. Two studies used the
MINI instead of the longer SCID, the limitations of which
are discussed above. One study by Haller et al. used the
Minnesota Multiphasic Personality Inventory (MMPI),
Structured Interview for DSM-III-R Personality Disorders
(SIPD-R), and Millon Clinical Multiaxial Inventory (MCMI-
II) self-report questionnaires to aid in determining diagnoses
and illness severity; the researchers stated that they conducted
standardized interviews for Axis I disorders but did not detail
how these were conducted [14].
Described below are the effects of dual diagnosis in preg-
nant women on (a) illness severity and functional impairment,
and (b) treatment adherence/completion.
Illness Severity and Functional Impairment
In order to assess illness severity and functional impairment in
pregnant women diagnosed with OUD and comorbid psychi-
atric disorders, a few of the studies utilized the Addiction
Severity Index (ASI), a semi-structured interview that evalu-
ates pretreatment impairment on seven domains (medical, em-
ployment, drug, alcohol, legal, family/social, and psychiatric)
and assigns a composite score to each domain [28]. In con-
trast, Haller et al. used self-report questionnaires and non-
SCID structured interviews to assess severity of illness, and
Chisolm et al. did not report a measure for illness severity [14,
22••]. Every study using ASI reported higher psychological
impairment scores in pregnant women with both OUD and
psychiatric comorbidity than in pregnant women with OUD
only. These studies also found that women with both OUD
and psychiatric comorbidity had higher composites scores of
family/social impairments.
Eggleston et al. and Moylan et al. investigated the relation-
ship between PTSD and SUD in pregnancy by using the SCID
[15, 16••]. Moylan et al. found that women with both SUD
and PTSD exhibited greater impairment in the ASI
Psychological and Family/Social Domains as compared to
women with SUD only or women with both SUD and non-
PTSD Axis I disorders. Eggleston et al. found that pregnant
women with both SUD and PTSD had higher rates of the
following conditions within the ASI Psychological
Impairment Domain (as compared to pregnant women with
SUD only or SUD and a non-PTSD Axis I disorder): suicidal
ideation (lifetime adjusted and within the last 30 days), suicide
attempts (lifetime adjusted), and trouble controlling violence
(lifetime adjusted and in the last 30 days). Pregnant women
with both SUD and PTSD also had higher rates of the follow-
ing conditions in the ASI Family/Social Domains: problemat-
ic relationships, homelessness, and illegal behaviors.
Pregnant women with SUD and copsychiatric disorders do
not necessarily havemore severe SUD at treatment entry. Four
studies found no differences in the drug and alcohol use do-
mains between pregnant women with and without psychiatric
comorbidities, suggesting that substance use disorder severity
is comparable between participants with and without psychi-
atric comorbidity [15, 16••, 21, 30]. It should be noted that
part of what is being seen in the lack of severity in the SUD
domain relates to a relative ceiling effect seen in patients with
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Table 2 Impact of cooccurring psychiatric disorders
Author (year of
publication)
Title Method Question Results Limitations
Fitzsimons HE, Tuten
M, Vaidya V, Jones
HE (2007)
Mood disorders affect
drug treatment success
of drug-dependent
pregnant women
Cohort;
(N = 106)
What is the impact of
cooccurring Axis I
disorders on drug
treatment outcomes of
drug-dependent
pregnant women?
Mood Disorder (MD)
and Anxiety Disorder
(AD) groups had
higher incidence of
psychosocial
impairment and
suicidal ideation; AD
spent more time in
treatment than MD or
No Diagnosis (ND)
group; MD group had
more positive urine
screens than AD and
ND groups; confirms
previous findings that
MD poorly affects
treatment outcomes;
new finding that Ad
did not negatively
affect tx; ASI scores
similar in AD, MD
and ND groups over 5
domains, MD and AD
groups had higher
scores on psychiatric
and family/social hx
composite scores.
Recall bias; portion of
participants left prior
to data collection, may
limit generalizability;
no tracking of psych
symptoms, only initial
assessment; symptom
overlap with 44% of
MD having anxiety
and 35% of AD group
having depression;
Benningfield MM,
Dietrich MS, Jones
HE, Kaltenbach K,
Heil SH, Stine SM,
Coyle MG, Arria
AM, O’Grady KE,
Fischer G, Martin PR
(2012)
Opioid dependence
during pregnancy:
relationships of
anxiety and
depression symptoms
to treatment outcomes.
Secondary
Analysis of
an RCT
(N = 175)
What is the relationship
of anxiety and
depression with
treatment outcome in
opioid-dependent
pregnant women?
What are their
psychotropic
medications?
In terms of treatment
attrition
AD(47%) > AD +
MD (25%) = ND
(18.2%) > MD
(10.5%) No difference
were observed with
ongoing illicit drug
use or pre-term
delivery; ASI
psychological
composite score was
higher for AD, MD,
and AD + MD, than
ND group; no
significant association
found between ASI
score and
discontinuation of tx;
a trend was found
toward more urines
with illicit substances
and the MD + AD
group, but it was not
statistically
significant; no
statistically significant
association between
psychiatric symptoms
and pre-term delivery
Only brief screening tool
for psych symptoms;
so no confirmative
psych diagnosis; only
initial screening;
threshold for anxiety
and depression
symptoms lower that
what is needed for
formal dx; no
longitudinal measure;
psychosocial
treatments were not
standardized;
secondary analysis
makes statistical
power limited, results
should be considered
exploratory;
psychiatric tx not
necessary provided by
study staff
Haller DL, Miles DR,
Dawson KS (2002)
Psychopathology
influences treatment
retention among
Cohort (N = 78) What is the relationship
between psychiatric
morbidity (including
personality disorders)
Study controlled for
structural barriers that
impede program
participation; Group
Use self-report tools to
evaluate symptoms
and diagnoses; did not
use SCID “gold
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Table 2 (continued)
Author (year of
publication)
Title Method Question Results Limitations
drug-dependent
women.
and treatment drug out
in a group of pregnant
drug dependent
women?
of patients with most
severe
psychopathology had
highest dropout rate,
even though they did
not have most severe
substance use disorder
diagnosis. Group with
significant substance
dependence and
predominant
borderline personality
disorder had the
highest retention rate
compared with group
with little
psychopathology and
group with more
severe
psychopathology.
standard” to get DSM
diagnoses; Only 9% of
patients abusing
opiates, most 87%
abusing cocaine; only
9% opioids
Eggleston AM, Calhoun
PS, Svikis DS, Tuten
M, Chisolm MS,
Jones HE (2009)
Suicidality, aggression,
and other treatment
considerations among
pregnant,
substance-dependent
women with
posttraumatic stress
disorder.
Cross-sectional
(N = 105)
What is the relationship
between PTSD and
SUD and does it
confer greater risk and
severity than what is
seen with SUD and
other Axis I disorders?
Three study groups
evaluated
(SUD-PTSD,
SUD-PSY and
SUD-only) showed
equivalent substance
use severity, however
the SUD-PTSD group
had higher odds of
reporting suicidality,
aggression, and
psychosocial
impairment (more
problematic
relationships, more
illegal behavior, more
homelessness) than
both the SUD-PSY
and SUD-only groups.
SUD-PTSD groups
had high rate of other
Axis I diagnoses,
similar to that in the
SUD-PSY group.
Rates and numbers of
substances used did
not differ
Majority of patients had
opioid use disorder,
11% had cocaine use
disorder and not
opioid; small sample
size; psychotic illness
was excluded;
homogeneous sample
in terms of substance
use severity
Moylan PL, Jones HE,
Haug NA, Kissin
WB, Svikis DS
(2001)
Clinical and
psychosocial
characteristics of
substance-dependent
pregnant women with
and without PTSD.
Cross-sectional
(N = 123)
How does the psychiatric
and psychosocial
functioning of opiate
or cocaine dependent
pregnant women with
and without a
diagnosis of PTSD
differ?
Women with a diagnosis
of PTSD had higher
rates of Axis I and
Axis II diagnosis than
opiate or cocaine
dependent women
without PTSD.
Women with PTSD
had higher levels of
emotional, physical
and sexual abuse,
higher rates of suicide
attempts, higher ASI
impairment on
Low rate of PTSD in
sample population
(19%), which is low
compared to other
samples with
addictions, authors
suggest due to
assessment being
made early in
treatment when
patients less likely to
disclose trauma; only
1 measure used to
assess PTSD; Not all
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OUD where they are all so severe that it is difficult to find
differences in this domain. In contrast, Benningfield et al.
found a difference in the drug use domain, which might be
explained by the study’s use of the MINI to screen for psychi-
atric symptoms. Specifically, they reported more severe sub-
stance use in patients with major depressive disorder, gener-
alized anxiety disorder, hypomania, dysthymia, PTSD, and
suicidality [18]. Neither Eggleston et al. nor Moylan et al.
found higher drug and alcohol composite scores or ASI
individual items among pregnant women with PTSD as com-
pared to women without PTSD [15, 16••]. Haller et al. found
that patients with greater psychopathology had similar sub-
stance use patterns when compared to patients with lower
psychopathology, with severity evaluated using MMPI,
SIPD-R, and MCMI-II self-report questionnaires [14]. The
researchers used psychopathology based clusters to create
three groups ranked by severity of psychopathology from
low (i.e., SUD only, “benign” psychiatric comorbidities
Table 2 (continued)
Author (year of
publication)
Title Method Question Results Limitations
family/social and
psychiatric domains.
Severity of substance
use disorder and group
attendance did not
differ in women with
and without PTSD.
women opioid
addicted; some
cocaine only; 56%
were on methadone
maintenance
Benningfield MM Arria
AM, Kaltenbach K,
Heil SH, Stine SM,
Coyle MG, Fischer
G, Jones HE, Martin
PR (2010)
Cooccurring psychiatric
symptoms are
associated with
increased
psychological, social,
and medical
impairment in opioid
dependent pregnant
women.
Secondary
analysis of an
RCT
(N = 174)
What is the relationship
of psychiatric
symptoms to severity
of drug use and drug
related problems
among pregnant
women with opioid
use disorder?
Majority of sample
(50.3%) screened
positive for
cooccurring
psychiatric illnesses,
these patients had
increased psychiatric
and social impairment
as measured by ASI;
the impaired domains
on ASI varied by
cooccurring diagnosis;
the drug domain was
more impaired in
subjects diagnosed
with MDD and
Dysthymia but not
other illnesses; the
sample showed a low
prevalence for PTSD
of only 16% and high
prevalence of
hypomania of 39%
MINI screener used to
establish symptoms
and diagnosis with no
SCID, so the meaning
of rates of illness are
not well established;
only symptoms at
intake were measured
and no longitudinal
assessment of how
these progressed
during pregnancy;
Axis II disorders not
evaluated
Chisolm MS, Tuten M,
Brigham EC, Strain
EC, Jones HE (2009)
Relationship between
cigarette use and
mood/anxiety
disorders among
pregnant
methadone--
maintained patients.
Cross-Sectional
(N = 112)
What is the association
between cigarette
smoking during
pregnancy and
psychiatric illness in a
population of pregnant
substance-dependent
patients?
Study finds high rate of
smoking (88%) in
their sample and
smoking (yes/no) was
correlated with current
symptoms of anxiety
or depression, but
amount of smoking (#
of cigarettes) did not
correlate with
presence psychiatric
illness; the rate of use
of nonopioid
substance use did not
differ between women
who smoked and
those who did not
Cross-sectional nature of
the data precludes
mechanisms from
being assessed;
self-report of smoking
used with no biologic
confirmations;
assessment of
psychiatric illness
only performed at
treatment entry;
sample size is small
and unequal group
size impact power to
detect differences
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identified outside the SUD) to moderate (Axis II and SUD) to
high (Axis I disorders and SUD), based on MCMI-II Base
Rate Scores. Benningfield et al. found no significant differ-
ences in substance use between participants in four groups
(with putative diagnoses based on the MINI diagnostic tool):
depressive disorders and SUD; anxiety disorders and SUD;
anxiety, depressive disorders, and SUD; and SUD only.
Based on the studies by Fitzimmons et al., Eggleston et al.,
Moylan et al., and Haller et al., it appears that measuring SUD
severity alone is insufficient to determine illness severity and
functional impairment in pregnant women entering OUD
treatment.
The studies reviewed had differing rates of poly-substance
use in pregnant women with OUD with or without comorbid
psychiatric disorders, and not all the studies reviewed ad-
dressed this parameter. Eggleston et al. found no difference
in poly-substance use at treatment entry, other than for tobacco
use, which was higher in women with comorbid PTSD, but
not other non-SUD psychiatric illnesses [16••]. Chisolm et al.
found that pregnant women with OUD and psychiatric comor-
bidity were more likely to smoke tobacco than those without
psychiatric comorbidity, but in this study, PTSD was not an-
alyzed separately from other non-SUD-psychiatric illnesses
[22••]. Benningfield et al. found statistically significant differ-
ence in ASI Drug use domain for patients with major depres-
sive disorder, generalized anxiety disorder, hypomania, dys-
thymia, and PTSD, when compared to patients with OUD
only, but did not discuss rates of nicotine use [23]. Moylan
et al. reported 89% poly-substance use in their sample, and
76% nicotine use but did not discuss whether rates were dif-
ferent in subjects with and without non-SUD psychiatric ill-
nesses [15].
Treatment Adherence and Completion
A literature review by Greenfield et al. found that pregnant
women with SUD and psychiatric comorbidities have lower
treatment retention rates than women without psychiatric co-
morbidities [29]. This literature review had similar results
when focusing on the subpopulation of pregnant women with
OUD and psychiatric comorbidities.
Haller et al. reported that participants with the most severe
psychopathology (those with SUD andAxis I disorders, includ-
ing patients with psychotic illness) had the highest dropout rates
and fastest attrition rate, with only 33% completing treatment.
The group with the least severe psychopathology (participants
with SUD only) had a lower dropout rate (57% completed
treatment). Interestingly, the group with moderate psychopa-
thology (participants with SUD and Axis II disorders) had the
lowest dropout rate (76% completed treatment) [14]. The group
with the least severe psychopathology may have had relatively
high dropout rates because they needed fewer services, while
the group with the most severe psychopathology’s relatively
high dropout rate could be due to a lack of appropriate services.
Surprisingly, a large percentage of patients with personality
disorders completed treatment despite generally being consid-
ered “difficult to treat.” However, the program was specifically
designed for patients with personality disorders, including a
“holding environment” [14].
The literature presents conflicting results on the correlation
between cooccurring psychiatric disorders and treatment ad-
herence. Fitzsimmons et al. studied a population undergoing
methadone treatment and found a correlation between anxiety
diagnoses and better treatment adherence and retention (dem-
onstrated by greater number of days in treatment, longer time
in programming on treatment days, and fewer positive urine
tests) as compared to patients with primary depression diag-
noses or no anxiety or depression diagnoses [26••]. In con-
trast, Benningfield et al. found that patients with putative de-
pressive diagnoses were relatively more likely to be retained
in treatment than patients without putative depressive diagno-
ses, and patients with putative anxiety diagnoses were more
likely to leave treatment than patients without putative anxiety
diagnoses [17].
Moylan et al., surprisingly, found no statistically significant
difference in treatment retention between groups of patients
with and without PTSD (17.3 vs. 15.7 days) [15]. Similarly,
Eggleston et al. found no statistically significant differences
between urines drug screens of subjects with SUD only, SUD
and Axis I Disorders, and subjects with PTSD and SUD
[16••]. However, more research into the relationship between
cooccurring PTSD and treatment retention is needed, especial-
ly given the frequency with which PTSD occur alongside
other psychiatric comorbidities as discussed above.
Discussion
Per this literature review, 25–33% of pregnant women with
OUD have a psychiatric comorbidity, with depression and
anxiety being especially common. However, these results
must be interpreted with caution. Only one study reviewed
by the authors (Benningfield et al. 2010) met all the following
criteria: reported the prevalence rates as primary research out-
come, used a validated screening method, and occurred in the
last 10 years. While the authors report a range of prevalence
rates from other studies, they must be interpreted with caution
given inconsistency in screening methods and research ques-
tions. Furthermore, some studies reported prevalence rates
prior to treatment initiation, while others reported screening
rates after treatment initiation. Future studies should report
prevalence rates for both time periods. Additionally, the au-
thors suspect that rates of cooccurring psychiatric conditions
may be underreported during screening, especially consider-
ing stigma and fear of reporting requirements to authorities
( such as Depar tments of Chi ld Serv ices ) . The
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environment within which screening is conducted, includ-
ing empathy exhibited by the researcher or clinician, may
affect accuracy of reported results. Due to all the limita-
tions discussed above, the rates reported in this review
must be viewed with caution. There is a clear need for a
more comprehensive population-based study on pregnant
women with OUD to determine rates of various comorbid
psychiatric conditions in this population.
Based on this literature review, it appears that that
complications brought upon by psychiatric comorbidities
are not reflected simply in greater severity of opioid use
disorder but are also reflected in the degree to which the
woman’s psychiatric, family, and social functioning is
impaired. The data reviewed further suggests cooccurring
psychiatric morbidities impact treatment adherence in
pregnant women with OUD and that retaining pregnant
women with OUD in treatment improves with integrated
treatment of their addictive and nonaddictive mental ill-
nesses. Interestingly, several studies found that women
with OUD and diagnoses of depressive disorders, anxiety
disorder, and PTSD were more likely to adhere to treat-
ment than women with OUD only [12, 13, 18, 27]. These
higher rates of adherence for women with anxiety and
depression, and even PTSD, were found at treatment set-
tings that provided integrated obstetrics and addiction
treatment along with treatment for their cooccurring psy-
chiatric illnesses and increased social support, which may
suggest that the treatment settings that address these
cooccurring illnesses may differentially benefit women
diagnosed with these disorders. Other possible hypothe-
ses for this finding include greater perceived need for
care, greater familiarity with the healthcare system, and
less stigma regarding being diagnosed with a psychiatric
illness. However, it is difficult to have confidence in
these results due to several design flaws in the studies
including small sample sizes ranging from 78 to 174,
use of different instruments to diagnose the comorbid
diagnosis, variable time courses, and assessed adherence
by different measures. Also, two of the studies did not
have treatment adherence as the primary goal of the
study, which is of significant concern [21].
Previous work has demonstrated that treatment for
pregnant women with OUD is most effective when it
is gender-specific, provides comprehensive care, and ad-
dresses the unique barriers these women face, and this
review confirms this and adds that the dimension of
comorbid mental illness is a particularly important area
to attend to [29–31]. The authors recommend that pay-
ing special attention to the specific needs of the pa-
tients’ psychiatric disorder is vital to retention and both
treatment type (individual or group) and intensity (inpa-
tient, partial program, intensive outpatient program, or
weekly group therapy) will be differentially effective for
patients with different mental illnesses. Patients with
personality disorders, for example, can be engaged in
and complete treatment if the program considers their
pathology and a developmentally appropriate treatment
approach [14]. The many social and family impairments
that complicate the lives of pregnant women with
PTSD, and the greater difficulty in trusting treatment
providers, also necessitate special attention to trauma-
informed care and some modulation of the usual con-
frontational style of many SUD programs. In particular,
pregnant women with SUD’s tend to experience a sig-
nificant amounts of guilt, shame, and fear of DCS re-
moval of their children, which is both a substantial bar-
rier to entering treatment, but also to remaining in treat-
ment, and thus a nonjudgmental, nonpunitive environ-
ment is particularly important for treating this popula-
tion [5]. These considerations cannot be attended to if
providers that treat pregnant women are not aware of
patients’ psychiatric and/or addictive illnesses; thus, this
review adds poignancy to the need to integrate screen-
ing and diagnosis of these disorders to routine prenatal
care of all women. Additionally, the rates of poly-
substance use were found to be extremely high (up
93% if nicotine is included, and up to 86% when
not), and thus treatment of women with OUD must also
include specific treatments for the other SUD, including
nicotine, the cravings for which will not be treated by
the MAT that often helps manage OUD [16••, 26••].
The authors see a pressing need for more studies with
larger sample sizes, validated diagnostic tools, and longi-
tudinal study methods. Studies reporting treatment adher-
ence should include measures such as days in treatment,
time spent in treatment each day, and urine drug screen
results during treatment. Also, measures of progression
through stages of change, measures of social, family,
and relationship functioning, and changes in engagement
with general medical care would provide more details
about how subjects are affected by the treatment and
how to optimize programing. Research to evaluate differ-
ent types of therapy, effects of environmental factors, and
medication management approaches in this population are
also needed.
This review and other studies recommend integrating
prenatal care and addictions treatment and psychiatric care
in one setting is preferred for pregnant women [32].
Further research is still needed to compare providing pre-
natal care in a dual diagnosis setting or address psychiat-
ric illnesses in an Ob-Gyn setting. Benefits to providing
the care in a dual diagnosis setting might include the
greater availability of dual diagnosis treatment and conti-
nuity of care following delivery when there is a reduction
in contact with an Ob-Gyn provider. Benefits to providing
the treatment in an Ob-Gyn setting include lower stigma
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and patient comfort for some patients. Additionally, the
authors suggest including a measure of participants’ ex-
perience with and ownership of their treatment. Some eth-
nographic studies that give a greater and more detailed
picture of the women’s experience with treatment pro-
viders and programs would be essential for designing
patient-centered and empowering programming. Such
studies exist for the general population of pregnant wom-
en with SUD, but few are specific to pregnant women
with OUD and psychiatric comorbidities [33–36].
In addition, although a large randomized controlled tri-
al have established the equivalence of methadone and
buprenorphine for OUD treatment during pregnancy, the
authors did not identify any randomized controlled trials
that evaluated different types of psychiatric treatments
(medication or therapy) for cooccurring psychiatric disor-
ders pregnant women experience [37]. There is limited
guidance on combining different psychiatric medications
for treatment of co-occurring psychiatric illnesses in the
setting of either methadone or buprenorphine in pregnant
women. Given that a large percentage of pregnant women
with OUD may already be taking psychiatric medication,
and because psychiatric medications can impact metabo-
lism, response to treatment, birth, and neonatal outcomes,
more research into medication management for this sub-
population is needed.
Conclusions
On balance, this review highlights the complexity facing
many providers who work with pregnant women with
OUD as these women tend to have high rates of psy-
chiatric comorbidity and multiple SUD’s along with
complicated social and family dimensions. More studies
are needed of the comorbid psychiatric conditions af-
fecting pregnant women with OUD to create an evi-
dence base from which to draw when establishing treat-
ment programs to address the needs of this population.
Assessment of psychiatric comorbidity and SUD should
be a part programing with concurrent treatment; howev-
er, precise recommendations on treatment setting, thera-
py modalities, and medication management all require
further research.
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Appendix.
Database: Ovid MEDLINE(R) <1946 to September Week 4
2016>, Ovid MEDLINE(R) Daily Update <October 03,
2016>, Ovid
MEDLINE(R) In-Process & Other Non-Indexed Citations
<October 03, 2016>
Search Strategy:
1. exp Demography/ (1147703)
2. exp population characteristics/ (1650409)
3. exp Pregnancy Outcome/ or exp Pregnancy Rate/ or exp
Pregnancy/ or exp Pregnancy, Unplanned/ or exp
Pregnancy,
4. Unwanted/ or exp Pregnancy Complications/ or exp
Pregnancy, Prolonged/ or exp Time-to-Pregnancy/
(838186)
5. exp Opiate Substitution Treatment/ or exp Opioid-Related
Disorders/ (21716)
6. exp Geographic Mapping/ (664)
7. exp Geography, Medical/ (1597)
8. 1 or 2 or 5 or 6 (1651533)
9. 3 and 4 and 7 (161)
10. 3 and 4 (1075)
11. 9 not 8 (914)
12. limit 10 to comment (33)
13. 10 not 11 (881)
14. limit 12 to (English language and humans) (719)
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